News:
ePaper |
Front Page |
National |
Tamil Nadu |
Andhra Pradesh |
Karnataka |
Kerala |
New Delhi |
Other States |
International |
Opinion |
Business |
Sport |
Miscellaneous |
Engagements |
Advts:
Retail Plus |
Classifieds |
Jobs |
Obituary |
Andhra Pradesh
‘India lags behind in clinical R&D’
Special Correspondent
VISAKHAPATNAM: Though India is a generic drug super power, no single drug on a new molecule has been discovered here during the last two decades or more.
Research and Development in drugs is a long drawn process, running to 14 years before it is introduced in the market; for every 5,000 molecules only one reaches the market which is a blockbuster and there is a 42 per cent chance of it being withdrawn before its life time.
All these factors make the drugs expensive. These facts w’ere stated by Director of Arkus Clinical Trial Support Solutions (Ahmedabad) Anupama Ramkumar while speaking at a seminar on ‘International clinical trials in India-what every one should know’ here.
A good number of students and youth attended the talk during which Dr. Anupama also explained about the career opportunities.
It was not true that the foreign companies were using Indians as guinea pigs to test their drugs. First the drugs are tested on animals and the maximum lethal dose used on the humans were one hundredth of what was used on animals.
The clinical trails consist of four phases: safety studies, therapeutic exploratory trials, therapeutic confirmatory trials and post-marketing surveillance.
It is also mandatory that data is collected from 1,500 people who volunteered for the first three phases. Medha Molecules Research Limited director Parameswara Rao presided.
Printer friendly
page
Send this article to Friends by
E-Mail
Andhra Pradesh
News:
ePaper |
Front Page |
National |
Tamil Nadu |
Andhra Pradesh |
Karnataka |
Kerala |
New Delhi |
Other States |
International |
Opinion |
Business |
Sport |
Miscellaneous |
Engagements |
Advts:
Retail Plus |
Classifieds |
Jobs |
Obituary |
Updates:
Breaking News |
|